pargyline has been researched along with Coronary Heart Disease in 3 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lamontagne, D | 1 |
| Yamaguchi, N | 1 |
| Ribuot, C | 1 |
| de Champlain, J | 1 |
| Nadeau, R | 1 |
| Carlsson, L | 1 |
| Graefe, KH | 1 |
| Trendelenburg, U | 1 |
| Vidt, DG | 1 |
3 other studies available for pargyline and Coronary Heart Disease
| Article | Year |
|---|---|
Reduction of tissue noradrenaline content in the isolated perfused rat heart during ischemia: importance of monoamine oxidation.
Topics: Animals; Coronary Disease; In Vitro Techniques; Male; Monoamine Oxidase; Myocardium; Norepinephrine; | 1991 |
Early intraneuronal mobilization and deamination of noradrenaline during global ischemia in the isolated perfused rat heart.
Topics: Animals; Calcium; Coronary Circulation; Coronary Disease; Deamination; Desipramine; Heart; In Vitro | 1987 |
An approach to the medical treatment of hypertension in the aged.
Topics: Age Factors; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Diuretics; | 1969 |